Lexicon Pharmaceuticals Inc. (LXRX) Given Average Recommendation of “Hold” by Brokerages
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) has earned an average recommendation of “Hold” from the nine research firms that are presently covering the company. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $24.20.
LXRX has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, August 11th. Zacks Investment Research raised Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 3rd. Citigroup Inc. initiated coverage on Lexicon Pharmaceuticals in a report on Tuesday, August 2nd. They set a “buy” rating and a $21.00 price objective for the company. Stifel Nicolaus lifted their price objective on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday, September 20th.
TRADEMARK VIOLATION WARNING: “Lexicon Pharmaceuticals Inc. (LXRX) Given Average Recommendation of “Hold” by Brokerages” was originally posted by Financial Market News and is the sole property of of Financial Market News. If you are reading this report on another publication, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this report can be viewed at http://www.financial-market-news.com/lexicon-pharmaceuticals-inc-lxrx-given-average-recommendation-of-hold-by-brokerages/1208646/.
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded up 1.06% during midday trading on Tuesday, reaching $16.20. 171,415 shares of the company’s stock were exchanged. The company’s market capitalization is $1.69 billion. Lexicon Pharmaceuticals has a 1-year low of $7.65 and a 1-year high of $19.62. The firm has a 50-day moving average of $16.17 and a 200-day moving average of $15.61.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.14. The firm earned $27.70 million during the quarter, compared to analysts’ expectations of $9.68 million. Lexicon Pharmaceuticals had a negative return on equity of 9.46% and a negative net margin of 11.87%. Lexicon Pharmaceuticals’s quarterly revenue was up 4763.2% compared to the same quarter last year. During the same period last year, the business earned ($0.34) earnings per share. Equities analysts expect that Lexicon Pharmaceuticals will post ($1.57) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of LXRX. Paradigm Asset Management Co. LLC bought a new position in Lexicon Pharmaceuticals during the second quarter valued at about $115,000. First Mercantile Trust Co. raised its position in Lexicon Pharmaceuticals by 9.2% in the second quarter. First Mercantile Trust Co. now owns 10,700 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 900 shares during the last quarter. Alambic Investment Management L.P. bought a new position in Lexicon Pharmaceuticals during the second quarter valued at about $165,000. WMS Partners LLC bought a new position in Lexicon Pharmaceuticals during the third quarter valued at about $181,000. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in Lexicon Pharmaceuticals during the second quarter valued at about $195,000.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.